Drugs that contain Mesalamine
1. Apriso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6551620 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8496965 | SALIX | Pellet formulation for the treatment of the intenstinal tract |
Apr, 2018
(6 years ago) | |
| US8940328 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8911778 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8337886 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8956647 | SALIX | Pellet formulation for the treatment of the intestinal tract |
Apr, 2018
(6 years ago) | |
| US8865688 | SALIX | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 31, 2011 |
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis; For the maintenance of remission of ulcerative colitis in subjects 18 years of age and older
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
APRISO family patents
2. Asacol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541170 | APIL | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US5541171 | APIL | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
Market Authorisation Date: 31 January, 1992
Treatment: Treatment of ulcerative colitis
Dosage: TABLET, DELAYED RELEASE;ORAL
ASACOL family patents
3. Asacol Hd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
| US8580302 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
| US6893662 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
| US9089492 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
Market Authorisation Date: 29 May, 2008
Treatment: Treatment of ulcerative colitis
Dosage: TABLET, DELAYED RELEASE;ORAL
ASACOL HD family patents
4. Canasa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8436051 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
| US8217083 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Sep 02, 2019 |
Market Authorisation Date: 05 November, 2004
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
CANASA family patents
5. Delzicol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
| US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US6649180 | ABBVIE | Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups |
Apr, 2020
(4 years ago) | |
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DELZICOL family patents
6. Lialda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6773720 | TAKEDA PHARMS USA | Mesalazine controlled release oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 26, 2023 |
| New Indication(I-640) | Jul 14, 2014 |
Market Authorisation Date: 16 January, 2007
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL
LIALDA family patents
7. Sfrowasa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7645801 | MYLAN SPECIALITY LP | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
Jul, 2027
(3 years from now) | |
Market Authorisation Date: 24 December, 1987
Treatment: NA
Dosage: ENEMA;RECTAL
SFROWASA family patents